

# Chiara Porta

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5833450/chiara-porta-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38  
papers

4,823  
citations

23  
h-index

39  
g-index

39  
ext. papers

5,538  
ext. citations

7.5  
avg, IF

5.3  
L-index

#	Paper	IF	Citations
38	Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	2
37	Extracellular nicotinamide phosphoribosyltransferase boosts IFN $\gamma$ -induced macrophage polarization independently of TLR4.. <i>IScience</i> , <b>2022</b> , 25, 104147	6.1	1
36	Recent Advances in Biomedical, Therapeutic and Pharmaceutical Applications of Microbial Surfactants. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	15
35	Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	5
34	Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. <i>Journal of Molecular Medicine</i> , <b>2020</b> , 98, 595-612	5.5	13
33	The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	9
32	Tumor-Derived Prostaglandin E2 Promotes p50 NF- $\kappa$ B-Dependent Differentiation of Monocytic MDSCs. <i>Cancer Research</i> , <b>2020</b> , 80, 2874-2888	10.1	42
31	Myeloid-Derived Suppressor Cells: Ductile Targets in Disease. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 949	8.4	50
30	Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy. <i>FEBS Journal</i> , <b>2018</b> , 285, 717-733	5.7	34
29	Protumor Steering of Cancer Inflammation by p50 NF- $\kappa$ B Enhances Colorectal Cancer Progression. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 578-593	12.5	27
28	Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition. <i>Oncotarget</i> , <b>2018</b> , 7, e1388485	7.2	23
27	NAMPT: A pleiotropic modulator of monocytes and macrophages. <i>Pharmacological Research</i> , <b>2018</b> , 135, 25-36	10.2	37
26	Metabolic influence on the differentiation of suppressive myeloid cells in cancer. <i>Carcinogenesis</i> , <b>2018</b> , 39, 1095-1104	4.6	16
25	Tumor-associated myeloid cells as guiding forces of cancer cell stemness. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 1025-1036	7.4	37
24	Metabolic regulation of suppressive myeloid cells in cancer. <i>Cytokine and Growth Factor Reviews</i> , <b>2017</b> , 35, 27-35	17.9	23
23	Macrophage polarization in pathology. <i>Cellular and Molecular Life Sciences</i> , <b>2015</b> , 72, 4111-26	10.3	337
22	RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis. <i>Cancer Cell</i> , <b>2015</b> , 28, 253-69	24.3	121

21	Molecular and epigenetic basis of macrophage polarized activation. <i>Seminars in Immunology</i> , <b>2015</b> , 27, 237-48	10.7	123
20	Hypoxia-mediated regulation of macrophage functions in pathophysiology. <i>International Immunology</i> , <b>2013</b> , 25, 67-75	4.9	58
19	Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). <i>Cancer Microenvironment</i> , <b>2012</b> , 5, 133-49	6.1	68
18	The p50 subunit of NF- $\kappa$ B orchestrates dendritic cell lifespan and activation of adaptive immunity. <i>PLoS ONE</i> , <b>2012</b> , 7, e45279	3.7	15
17	Macrophages in cancer and infectious diseases: the $\times$ good $\times$ and the $\times$ bad $\times$ . <i>Immunotherapy</i> , <b>2011</b> , 3, 1185-208	3.8	22
16	Mechanisms linking pathogens-associated inflammation and cancer. <i>Cancer Letters</i> , <b>2011</b> , 305, 250-62	9.9	81
15	IL-10 limits production of pathogenic TNF by M1 myeloid cells through induction of nuclear NF- $\kappa$ B p50 member in Trypanosoma congolense infection-resistant C57BL/6 mice. <i>European Journal of Immunology</i> , <b>2011</b> , 41, 3270-80	6.1	21
14	Convergent pathways of macrophage polarization: The role of B cells. <i>European Journal of Immunology</i> , <b>2010</b> , 40, 2131-3	6.1	18
13	Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 14978-83	11.5	452
12	Cellular and molecular pathways linking inflammation and cancer. <i>Immunobiology</i> , <b>2009</b> , 214, 761-77	3.4	210
11	Macrophage polarization in tumour progression. <i>Seminars in Cancer Biology</i> , <b>2008</b> , 18, 349-55	12.7	863
10	Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 29983-92	5.4	67
9	The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. <i>Critical Reviews in Oncology/Hematology</i> , <b>2008</b> , 66, 1-9	7	699
8	Linking inflammation reactions to cancer: novel targets for therapeutic strategies. <i>Advances in Experimental Medicine and Biology</i> , <b>2008</b> , 610, 112-27	3.6	33
7	Targeting tumour-associated macrophages. <i>Expert Opinion on Therapeutic Targets</i> , <b>2007</b> , 11, 1219-29	6.4	52
6	Inflammation and cancer: breast cancer as a prototype. <i>Breast</i> , <b>2007</b> , 16 Suppl 2, S27-33	3.6	164
5	Tumor promotion by tumor-associated macrophages. <i>Advances in Experimental Medicine and Biology</i> , <b>2007</b> , 604, 67-86	3.6	69
4	p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. <i>Cancer Research</i> , <b>2006</b> , 66, 11432-40	10.1	339

- 3 Tumor-associated macrophages (TAMs) as new target in anticancer therapy. *Drug Discovery Today: Therapeutic Strategies*, **2006**, 3, 361-366 10
- 2 Role of tumor-associated macrophages in tumor progression and invasion. *Cancer and Metastasis Reviews*, **2006**, 25, 315-22 9.6 667
- 1 Role of Tumor-Associated Macrophages (TAM) in Cancer Related Inflammation 77-98